GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Photo credit: Borja Ruiz Rodriguez/MSF

Time for $5

The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.

Letter: Civil society calls on UK Prime Minister to ensure UK-India free trade agreement does not threaten access to affordable medicines

Read, watch, share

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

MSF Position Paper: Ensuring Timely and Equitable Access to Medical Products in Global Public Health Emergencies

TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries

Colombia to challenge AIDS drug patents

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir